# Kilitch Drugs (India) (NSE: KILITCH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KILITCH · Pivot · prices to 30 Sep 2026

Kilitch Drugs (India) (NSE: KILITCH) closed at ₹215.00 on 30 Sep 2026. With a market capitalisation of ₹752 Cr, it ranks 1591st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 24.2× trailing earnings, against a return on equity of 10.8% in FY26. Over the past year the share price has risen 22.8%. Its 52-week range is ₹117.25 (30 Mar 2026) to ₹232.50 (24 Sep 2026); the last close is 7.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹90 Cr (+46.3% year on year) and net profit ₹15 Cr (+45.6%), on a consolidated basis. Promoters held 63.77% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹215.00 |
| Market cap | ₹752 Cr |
| P/E (trailing) | 24.2 |
| ROE | 10.8% (FY26) |
| ROCE | 13.2% (FY26) |
| Debt to equity | 0.32 |
| 52-week high | ₹232.50 (24 Sep 2026) |
| 52-week low | ₹117.25 (30 Mar 2026) |
| 1-year return | +22.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹90 Cr | +46.3% | ₹15 Cr | +45.6% | ₹4.24 |
| Q3 FY26 | ₹54 Cr | −4.2% | ₹4 Cr | −23.0% | ₹2.50 |
| Q2 FY26 | ₹49 Cr | +3.1% | ₹8 Cr | −6.6% | ₹4.97 |
| Q1 FY26 | ₹43 Cr | +29.0% | ₹2 Cr | +1,954.5% | ₹1.88 |
| Q4 FY25 | ₹61 Cr | +36.6% | ₹10 Cr | +177.7% | ₹6.47 |
| Q3 FY25 | ₹56 Cr | +76.7% | ₹6 Cr | +222.4% | ₹3.71 |
| Q2 FY25 | ₹47 Cr | +15.2% | ₹9 Cr | +69.2% | ₹5.36 |
| Q1 FY25 | ₹33 Cr | −8.5% | ₹0 Cr | −96.4% | ₹0.83 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹198 Cr | ₹25 Cr |
| FY24 | ₹154 Cr | ₹14 Cr |
| FY23 | ₹140 Cr | ₹8 Cr |
| FY22 | ₹114 Cr | ₹6 Cr |
| FY21 | ₹69 Cr | ₹4 Cr |
| FY20 | ₹53 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.77%
- Foreign institutions: 0.12%
- Domestic institutions: 0.00%
- Non-institutions: 36.11%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Anuh Pharma](https://app.pivotnow.in/stock/ANUHPHR) | ₹80.29 | ₹805 Cr | 19.6 | — |
| [Vikram Thermo](https://app.pivotnow.in/stock/VIKRAMTH) | — | ₹728 Cr | — | — |
| [Zim Laboratories](https://app.pivotnow.in/stock/ZIMLAB) | ₹133.50 | ₹715 Cr | 112.2 | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |
| [Amanta Healthcare](https://app.pivotnow.in/stock/AMANTA) | ₹182.55 | ₹709 Cr | 42.2 | — |
| [Gaudium IVF and Women Health](https://app.pivotnow.in/stock/GAUDIUMIVF) | ₹95.11 | ₹692 Cr | 24.3 | — |

## Questions and answers

### What is the share price of Kilitch Drugs (India) today?

Kilitch Drugs (India) (NSE: KILITCH) last closed at ₹215.00 on 30 Sep 2026. Its 52-week high is ₹232.50 and its 52-week low is ₹117.25.

### What is the market cap of Kilitch Drugs (India)?

Kilitch Drugs (India)'s market capitalisation is ₹752 Cr (₹752 Cr) at the 22 Oct 2026 close, ranking 1591st among the NSE companies Pivot tracks.

### What is the P/E ratio of Kilitch Drugs (India)?

Kilitch Drugs (India) trades at a trailing P/E of 24.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 42.2.

### What is the ROE and ROCE of Kilitch Drugs (India)?

Return on equity was 10.8% in FY26 and return on capital employed was 13.2% in FY26 (consolidated figures).

### Is Kilitch Drugs (India) a debt-free company?

No. Kilitch Drugs (India)'s debt-to-equity ratio was 0.32 in FY26, with total debt of ₹59 Cr.

### What were Kilitch Drugs (India)'s latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Kilitch Drugs (India) reported revenue of ₹90 Cr, +46.3% year on year, and net profit of ₹15 Cr, +45.6% year on year.

### How has Kilitch Drugs (India) stock performed over the last year?

Kilitch Drugs (India)'s share price has risen 22.8% over the past year, +8.9% over three months and +22.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Kilitch Drugs (India)?

As of 30 Jun 2026: promoters 63.77%, foreign institutions 0.12%, domestic institutions 0.00%, non-institutions 36.11%.

### Who are Kilitch Drugs (India)'s competitors?

The listed Pharma & Healthcare companies closest to Kilitch Drugs (India) by market cap are Anuh Pharma, Vikram Thermo, Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.

### Is Kilitch Drugs (India) a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Kilitch Drugs (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KILITCH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.